FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on ...
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Provides 2025 Corporate Outlook ...
PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...
Monthly Prescribing Reference3 天
Nasal Spray Formulation of Bumetanide Under FDA Review
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
Medical News Today3 天
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Corstasis Therapeutics Inc. Announces FDA Acceptance of New Drug Application for Bumetanide ...
"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...
TheHealthSite6 天
US FDA Approves First Of Its Kind Ketamine-Based Nasal Spray To Treat Depression: Know All ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...